Updated Analysis and Patient-Reported Outcomes of CITYSCAPE: A Randomised, Double-Blind, Phase II Study of the anti-TIGIT Antibody Tiragolumab (Tira) + Atezolizumab (Atezo) Versus Placebo + Atezo As First-Line Treatment For PD-L1-Selected NSCLC
CITYSCAPE is the first randomised Phase II study of an anti-TIGIT antibody; the combination of tiragolumab + atezolizumab showed clinically meaningful improvement in ORR and PFS compared with placebo + atezolizumab in patients with metastatic PD-L1+ NSCLC. Here we present updated PFS, OS, and PROs.